Prevention of Influenza in High-Risk Groups: What Are the Vaccine Options and Strategies? - with CE

Gregory A. Poland, MD, is the director of Mayo Clinic's Vaccine Research Group, Editor-in-Chief for the journal “Vaccine" and founding president of the Edward Jenner Vaccine Society. During his presentation, Dr. Poland will review what the high-risk groups are, why influenza infection is so deadly in these groups, and outline vaccine options and strategies for protecting them from the documented elevated morbidity and mortality of this infection.

Gregory A. Poland, M.D., is the director of Mayo Clinic's Vaccine Research Group – a state-of-the-art research group and laboratory that seeks to understand the genetic drivers of viral vaccine response and investigates issues surrounding novel vaccines important to public health. The Poland lab has developed the field of viral vaccine immunogenetics, the immune response network theory, and the fields of vaccinomics and adversomics. Dr. Poland participates on many national and academic review committees has published over 485 peer-reviewed scientific articles and book chapters.

There is no conflict of interest for anyone with the ability to control content of the conference except Dr. Poland, who is a consultant with Merck, CSL Biotherapies, Avianax, Dynavax, Novartis Vaccines and Therapeutics, Emergent Biosolutions, Adjuvance, Microdermis, Seqirus, NewLink, Protein Sciences, GSK Vaccines, and Sanofi Pasteur.

To receive 1.25 nursing contact hours, participants must watch the entire webinar and complete the webinar evaluation. Upon completion of the evaluation, participants will be issued a certificate of completion.

Key:

Complete
Failed
Available
Locked
Prevention of Influenza in High-Risk Groups: What Are the Vaccine Options and Strategies?
Gregory A. Poland, MD, is the director of Mayo Clinic’s Vaccine Research Group, Editor-in-Chief for the journal “Vaccine” and founding president of the Edward Jenner Vaccine Society. During his presentation, Dr. Poland will review what the high-risk groups are, why influenza infection is so deadly in these groups, and outline vaccine options and strategies for protecting them from the documented elevated morbidity and mortality of this infection. You must register to access.
Medical Certificate